The number of new drugs intering the market is decreasing, and once the patent expires on an existing drug most drugs effectivly become free.
Most importantly we spend twice as much of our GDP on heathcare as most contires with universal heathcare for reduced benifits. If the numbers keep getting worse the government can get involved in the supply side of the equation without reducing benifits to patents.
The number of new drugs intering the market is decreasing, and once the patent expires on an existing drug most drugs effectivly become free.
Most importantly we spend twice as much of our GDP on heathcare as most contires with universal heathcare for reduced benifits. If the numbers keep getting worse the government can get involved in the supply side of the equation without reducing benifits to patents.